LONDON/COPENHAGEN, Dec 20(Reuters) - Novo Nordisk
said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected.
The lower-than-expected weight loss from the drug candidate deals a blow to the Danish drugmaker's ambitions for a successor to its popular Wegovy more powerful than Eli Lilly's Zepbound.
Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
(Reporting by Maggie Fick in London and Stine Jacobsen and Louise Rasmussen in Copenhagen, Ludwig Burger in Frankfurt; Editing by Josephine Mason and Catherine Evans)
Comments